Zolbetuximab

CAS No. 1496553-00-4

Zolbetuximab( —— )

Catalog No. M37695 CAS No. 1496553-00-4

Zolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin-18.2-positive cells through an immune effector mechanism.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 373 In Stock
5MG 620 In Stock
10MG 870 In Stock
25MG 1283 In Stock
50MG 1702 In Stock
100MG 2297 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Zolbetuximab
  • Note
    Research use only, not for human use.
  • Brief Description
    Zolbetuximab(IMAB362) is a monoclonal antibody that specifically targets Claudin-18.2.Zolbetuximab has potential antitumor activity, mediating killing of Claudin-18.2-positive cells through an immune effector mechanism.
  • Description
    Zolbetuximab (IMAB362) is a monoclonal antibody targeting Claudin-18.2. Zolbetuximab mediates specific killing of Claudin-18.2-positive cells through immune effector mechanisms. Zolbetuximab can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors.
  • In Vitro
    ——
  • In Vivo
    Animal Model:mouse BxPC-3-CLDN18.2, MIA PaCa-2-CLDN18.2 xenograft model Dosage:200 μg alone or with 50 mg/kg Gemcitabine Administration:i.v.; i.p. (Gemcitabine)Result:Inhibited tumor growth in two models, and prevented lung metastasis formation.Prolonged survival time, and lowered fractions of CLDN18.2+ cells in MIA PaCa-2-CLDN18.2 xenograft.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1496553-00-4
  • Formula Weight
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kyuno D, et, al. Claudin-18.2 as a therapeutic target in cancers: cumulative findings from basic research and clinical trials. Tissue Barriers. 2022 Jan 2;10(1):1967080.?
molnova catalog
related products